234 related articles for article (PubMed ID: 2848062)
21. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation.
Meyers JD; Reed EC; Shepp DH; Thornquist M; Dandliker PS; Vicary CA; Flournoy N; Kirk LE; Kersey JH; Thomas ED
N Engl J Med; 1988 Jan; 318(2):70-5. PubMed ID: 2827025
[TBL] [Abstract][Full Text] [Related]
22. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
van Prooijen HC; Visser JJ; van Oostendorp WR; de Gast GC; Verdonck LF
Br J Haematol; 1994 May; 87(1):144-7. PubMed ID: 7947238
[TBL] [Abstract][Full Text] [Related]
23. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin).
Zintl F; Färber I; Hermann J; Fuchs D; Prager J; Wutzler P
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):557-64. PubMed ID: 2480308
[TBL] [Abstract][Full Text] [Related]
24. Cytomegalovirus-seronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation. Considerations for blood banks.
Bowden RA; Sayers M; Gleaves CA; Banaji M; Newton B; Meyers JD
Transfusion; 1987; 27(6):478-81. PubMed ID: 2825381
[TBL] [Abstract][Full Text] [Related]
25. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant.
Bowden RA; Slichter SJ; Sayers MH; Mori M; Cays MJ; Meyers JD
Blood; 1991 Jul; 78(1):246-50. PubMed ID: 1648976
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus seroconversion in patients receiving intensive induction therapy prior to allogeneic bone marrow transplantation.
Kelsey SM; Newland AC
Bone Marrow Transplant; 1989 Sep; 4(5):543-6. PubMed ID: 2551435
[TBL] [Abstract][Full Text] [Related]
27. [Experiences with transfusion of CMV tested blood preparations after bone marrow transplantation].
Luboldt W; Henneberg-Quester KB; Schaefer UW; Beelen DW; Quabeck K; Thraenhart O
Beitr Infusionsther; 1990; 26():190-3. PubMed ID: 1703827
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant.
Bowden RA; Fisher LD; Rogers K; Cays M; Meyers JD
J Infect Dis; 1991 Sep; 164(3):483-7. PubMed ID: 1651360
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation.
Sullivan KM; Kopecky KJ; Jocom J; Fisher L; Buckner CD; Meyers JD; Counts GW; Bowden RA; Peterson FB; Witherspoon RP
N Engl J Med; 1990 Sep; 323(11):705-12. PubMed ID: 2167452
[TBL] [Abstract][Full Text] [Related]
30. The effect of granulocyte transfusions on the incidence of cytomegalovirus infection after allogeneic marrow transplantation.
Hersman J; Meyers JD; Thomas ED; Buckner CD; Clift R
Ann Intern Med; 1982 Feb; 96(2):149-52. PubMed ID: 6277215
[TBL] [Abstract][Full Text] [Related]
31. Prophylaxis of cytomegalovirus infection.
Bowden RA; Meyers JD
Semin Hematol; 1990 Apr; 27(2 Suppl 1):17-21; discussion 28-9. PubMed ID: 2160127
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for cytomegalovirus infection after human marrow transplantation.
Meyers JD; Flournoy N; Thomas ED
J Infect Dis; 1986 Mar; 153(3):478-88. PubMed ID: 3005424
[TBL] [Abstract][Full Text] [Related]
33. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection. An analysis of risk factors.
Paulin T; Ringdén O; Lönnqvist B; Wahren B; Nilsson B
Scand J Infect Dis; 1986; 18(3):199-209. PubMed ID: 3016884
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus infections after allogeneic bone marrow transplantation.
Winston DJ; Ho WG; Champlin RE
Rev Infect Dis; 1990; 12 Suppl 7():S776-92. PubMed ID: 2173107
[TBL] [Abstract][Full Text] [Related]
35. Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam Heart Transplant Program experience.
Balk AH; Weimar W; Rothbarth PH; Meeter K; Metselaar HJ; Mochtar B; Simoons ML
Infection; 1993; 21(4):195-200. PubMed ID: 8225620
[TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease.
Miller W; Flynn P; McCullough J; Balfour HH; Goldman A; Haake R; McGlave P; Ramsay N; Kersey J
Blood; 1986 Apr; 67(4):1162-7. PubMed ID: 3006831
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
[TBL] [Abstract][Full Text] [Related]
38. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
39. The transplanted kidney as a source of cytomegalovirus infection.
Ho M; Suwansirikul S; Dowling JN; Youngblood LA; Armstrong JA
N Engl J Med; 1975 Nov; 293(22):1109-12. PubMed ID: 171567
[TBL] [Abstract][Full Text] [Related]
40. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan.
Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kato S; Kasahara S; Iseki T; Yamaguchi T; Tojo A; Asano S
Eur J Haematol; 2008 Mar; 80(3):251-7. PubMed ID: 18081702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
